[ad_2]
The allergic conjunctivitis market is anticipated to grow in the coming years owing to the increased prevalence, better disease understanding along with the current advancements in the treatment.
LAS VEGAS, Sept. 4, 2023 /PRNewswire/ — DelveInsight’s Allergic Conjunctivitis Market Insights report includes a comprehensive understanding of current treatment practices, allergic conjunctivitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Allergic Conjunctivitis Market Report
- As per DelveInsight analysis, the allergic conjunctivitis market is expected to grow positively at a significant CAGR during the study period (2019–2032).
- As per the DelveInsight estimates among the 7MM, the United States has the highest prevalent population of allergic conjunctivitis.
- Globally, leading allergic conjunctivitis companies such as Bausch & Lomb Incorporated, Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others are developing novel allergic conjunctivitis drugs that can be available in the allergic conjunctivitis market in the coming years.
- Some key therapies for allergic conjunctivitis treatment include Ketotifen fumarate ophthalmic solution, Dextenza, OK-101, and others.
Discover which therapies are expected to grab the major allergic conjunctivitis market share @ Allergic Conjunctivitis Market Report
Allergic Conjunctivitis Overview
Allergic conjunctivitis is a common eye condition characterized by inflammation of the conjunctiva – the thin, transparent layer covering the white part of the eye and the inner surface of the eyelids. This condition occurs when the eyes come into contact with allergens, which are substances that trigger an allergic reaction in susceptible individuals. Allergic conjunctivitis can be seasonal or perennial, depending on the allergen exposure. Allergic conjunctivitis causes primarily include exposure to allergens such as pollen, dust mites, pet dander, and mold spores.
Common allergic conjunctivitis symptoms include itching, redness, excessive tearing, swollen eyelids, a gritty sensation in the eyes, and light sensitivity. In some cases, individuals might also experience nasal symptoms like sneezing, runny nose, and congestion as part of a broader allergic reaction. Allergic conjunctivitis diagnosis involves a thorough eye examination by a medical professional. They may inquire about the individual’s medical history and any known allergies.
Allergic Conjunctivitis Epidemiology Segmentation
The allergic conjunctivitis epidemiology section provides insights into the historical and current allergic conjunctivitis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The allergic conjunctivitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Allergic Conjunctivitis Prevalent Cases
- Allergic Conjunctivitis Type-specific Cases
- Allergic Conjunctivitis Gender-specific Cases
- Allergic Conjunctivitis Diagnosed and Treated Cases
Allergic Conjunctivitis Treatment Market
Numerous allergic conjunctivitis treatment options are available to alleviate allergic conjunctivitis symptoms. Over-the-counter antihistamine eye drops, available in various brands, can effectively reduce itching and redness by blocking the histamine response triggered by allergens. These drops provide quick relief and are generally safe for short-term use. Decongestant eye drops, which contain vasoconstrictors, may provide temporary relief from redness and swelling, but their prolonged use is not recommended due to potential rebound effects and risk of adverse reactions.
For more severe or persistent cases of allergic conjunctivitis, it’s advisable to consult a healthcare professional. They might recommend prescription-strength medications such as mast cell stabilizer eye drops or corticosteroid eye drops. Mast cell stabilizers work by preventing the release of histamine and other inflammatory compounds, offering long-term relief. Corticosteroid eye drops are potent anti-inflammatories that can provide rapid relief, but they are usually prescribed for short-term use due to the risk of side effects with prolonged use.
In addition to medications, avoiding known allergens is crucial in managing allergic conjunctivitis. Minimizing exposure to pollen, dust mites, pet dander, and other triggers can significantly reduce symptoms. Using air purifiers, washing bed linens frequently, and keeping windows closed during high pollen seasons are helpful practices. Maintaining good eye hygiene, such as avoiding rubbing the eyes, washing hands regularly, and using clean tissues, can prevent further irritation and potential infection. Cold compresses can provide temporary relief by soothing the eyes and reducing inflammation.
To know more about allergic conjunctivitis treatment, visit @ Allergic Conjunctivitis Treatment Drugs
Key Allergic Conjunctivitis Therapies and Companies
- Ketotifen fumarate ophthalmic solution: Bausch & Lomb Incorporated
- Dextenza: Ocular Therapeutix
- OK-101: Okyo Pharma
Learn more about the FDA-approved drugs for allergic conjunctivitis @ Drugs for Allergic Conjunctivitis Treatment
Allergic Conjunctivitis Market Dynamics
The allergic conjunctivitis market dynamics are expected to change in the coming years. The prevalence of allergies and the increasing exposure to environmental triggers such as pollen, dust, and pet dander play a significant role in driving the demand for effective treatments. As awareness about ocular health rises
In addition, allergic conjunctivitis market competition intensifies as companies strive to develop advanced formulations, enhance drug delivery methods, and address unmet needs such as prolonged relief and minimized side effects. Moreover, economic factors, regulatory policies, and evolving healthcare infrastructures further shape the allergic conjunctivitis market landscape, making it a dynamic arena with continuous advancements and evolving strategies to cater to the needs of those affected by allergic conjunctivitis.
However, certain factors may impede the growth of the allergic conjunctivitis market. These factors include challenges in accurately diagnosing allergic conjunctivitis, as symptoms can sometimes mimic other eye conditions. Furthermore, the allergic conjunctivitis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the allergic conjunctivitis market growth.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Allergic Conjunctivitis Companies | Bausch & Lomb Incorporated, Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others |
Key Allergic Conjunctivitis Therapies | Ketotifen fumarate ophthalmic solution, Dextenza, OK-101, and others |
Scope of the Allergic Conjunctivitis Market Report
- Therapeutic Assessment: Allergic Conjunctivitis current marketed and emerging therapies
- Allergic Conjunctivitis Market Dynamics: Conjoint Analysis of Emerging Allergic Conjunctivitis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Allergic Conjunctivitis Market Access and Reimbursement
Discover more about allergic conjunctivitis drugs in development @ Allergic Conjunctivitis Clinical Trials
Table of Contents
1. | Allergic Conjunctivitis Market Key Insights |
2. | Allergic Conjunctivitis Market Report Introduction |
3. | Allergic Conjunctivitis Market Overview at a Glance |
4. | Allergic Conjunctivitis Market Executive Summary |
5. | Disease Background and Overview |
6. | Allergic Conjunctivitis Treatment and Management |
7. | Allergic Conjunctivitis Epidemiology and Patient Population |
8. | Patient Journey |
9. | Allergic Conjunctivitis Marketed Drugs |
10. | Allergic Conjunctivitis Emerging Drugs |
11. | Seven Major Allergic Conjunctivitis Market Analysis |
12. | Allergic Conjunctivitis Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Allergic Conjunctivitis Pipeline
Allergic Conjunctivitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key allergic conjunctivitis companies, including Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, among others.
Allergic Conjunctivitis Epidemiology
Allergic Conjunctivitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted allergic conjunctivitis epidemiology in the 7MM.
Allergic Rhino-Conjunctivitis Market
Allergic Rhino-Conjunctivitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key allergic rhino-conjunctivitis companies, including Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, among others.
Allergic Rhino-Conjunctivitis Pipeline
Allergic Rhino-Conjunctivitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key allergic rhino-conjunctivitis companies, including Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:
Source link
[ad_2]
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
[ad_2]
